IMVT-1402

Phase 3

Immunovant, Inc. (IMVT)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '27

IMVTPhase 2$7.0B

IMVT-1402 Phase 2 Est. Readout

IMVT-1402• Chronic Inflammatory Demyelinating Polyneuropathy120

Sep 2027~Estimated

CT.gov

00%

May '27

IMVTPhase 2$7.0B

IMVT-1402 Phase 2 Est. Readout

IMVT-1402• Chronic Inflammatory Demyelinating Polyneuropathy210

May 2027~Estimated

CT.gov

00%

Development History

Oct '26

IMVTPhase 2$7.0B

✓Completed

IMVT-1402 Phase 2 Est. Readout

IMVT-1402• Chronic Inflammatory Demyelinating Polyneuropathy56

Oct 2026~Estimated

CT.gov

Competitive Landscape

0 competitors in Chronic Inflammatory Demyelinating Polyneuropathy

View Full Landscape

Drug Information

Target Indication

Chronic Inflammatory Demyelinating Polyneuropathy

Clinical Trial

NCT07032662

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IMVT

Immunovant, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

BatoclimabPhase 3

Thyroid Eye Disease

Batoclimab 680 milligrams (mg) subcutaneous (SC) weeklyPhase 2

Chronic Inflammatory Demyelinating Polyneuropathy

RVT-1401Phase 2

Myasthenia Gravis

IMVT-1401 (batoclimab)Phase 2

Graves Disease

ImeroprubartPhase 2

Chronic Inflammatory Demyelinating Polyneuropathy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts